Seres Q1 net loss $40.1M, VOWST sales $10.1M; SER-155 data expected Q3

Seres Therapeutics, Inc.

2024-Q1 EPS reported -$0.27

Net loss $40.1M vs $71.2M YoY; VOWST net sales $10.1M (642 units).
Received ~1,411 VOWST enrollment forms, ~1,083 new patient starts in Q1.
SER-155 Phase 1b Cohort 2 data readout expected end of Q3 2024.
Cash $111.2M; expects runway into Q4 2024; may draw $45M debt tranche or use ATM.
Marella Thorell appointed EVP and CFO following David Arkowitz's retirement.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Seres Therapeutics, Inc. reported first quarter 2024 results: revenue $10.1 million, net income $40.1 million.

Period: first quarter 2024
Revenue: $10.1 million
Net income: $40.1 million
Result: reported results

Exact text from the filing

BUSINESS UPDATES Continued market adoption of VOWST ® with approximately 1,411 patient enrollment forms received, approximately 1,083 new patient starts, and net sales of $10.1 million during Q1 2024, and accelerated net sales in March and April SER-155 Phase 1b placebo-controlled Cohort 2 clinical readout expected end of Q3 2024 Further microbiome therapeutic

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Seres Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-133766

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.